Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hematopoietic and Lymphatic System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm

Cancer Family

Hematopoietic and Lymphatic System Neoplasm

CI-CAN-00000022Explore in graph →

Non-malignant4,304 active trials98 approved drugs1,010 evidence items

NCIt: C35813

Overview
Statistics
Survival
Genomics60
Variants & evidence1010
Drugs99
Trials18827
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (736)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 30, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 301–325 of 736 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Rituximab-Conjugated DART Nanoformulation for CD20-Targeted Drug Delivery in Non-Hodgkin Lymphoma.
Md Musavvir Mahmud, Byoungjae Kong, Daiheon Lee et al. · Int J Nanomedicine · Jan 1, 2026 · PMID 42764913 · candidate dictionary pubmed
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
· Blood · 2009 · PMID 19357394 · validated civic_curation pubmed
Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
· Oncogene · 2002 · PMID 12476305 · validated civic_curation pubmed
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
· Leuk Res · 2010 · PMID 20537386 · validated civic_curation pubmed
The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.
· Haematologica · 1995 · PMID 7628753 · validated civic_curation pubmed
All trans retinoic acid in acute promyelocytic leukemia.
· Oncogene · 2001 · PMID 11704842 · validated civic_curation pubmed
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
· Blood · 2016 · PMID 27069254 · validated civic_curation pubmed

Showing 301–325 of 736 publications

← Previous
1
…
12
13
14
…
30
Next →

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

· Blood · 2016 · PMID 26837699 · validated civic_curation pubmed

Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study.

· J Clin Oncol · 2018 · PMID 30044693 · validated civic_curation pubmed

The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: an updated meta-analysis.

· Cancer Biomark · 2014 · PMID 25335741 · validated civic_curation pubmed

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

· N Engl J Med · 2019 · PMID 31665578 · validated civic_curation pubmed

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

· Leukemia · 2022 · PMID 35732829 · validated civic_curation pubmed

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

· Blood · 1998 · PMID 9746770 · validated civic_curation pubmed

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

· Blood · 2014 · PMID 25037629 · validated civic_curation pubmed

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

· Blood · 2007 · PMID 16960151 · validated civic_curation pubmed

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

· Blood · 2017 · PMID 28588020 · validated civic_curation pubmed

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

· J Clin Oncol · 2017 · PMID 28787259 · validated civic_curation pubmed

Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.

· Ann Hematol · 2014 · PMID 24801015 · validated civic_curation pubmed

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

· N Engl J Med · 2003 · PMID 12660384 · validated civic_curation pubmed

Midostaurin approved for FLT3-mutated AML.

· Blood · 2017 · PMID 28546144 · validated civic_curation pubmed

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

· N Engl J Med · 2014 · PMID 25207766 · validated civic_curation pubmed

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

· N Engl J Med · 2018 · PMID 29860938 · validated civic_curation pubmed

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

· Lancet Oncol · 2020 · PMID 33035457 · validated civic_curation pubmed

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.

· Oncotarget · 2017 · PMID 27894077 · validated civic_curation pubmed

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

· Lancet Oncol · 2018 · PMID 29650362 · validated civic_curation pubmed